Marie Bézenger Joins Deinove as Director of Operations

Regulatory News:

DEINOVE (Paris:ALDEI) (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, announced today that Marie Bézenger has joined the Executive Committee as Director of Operations. She will manage the downstream development of the fermentation processes and their scale-up to foster their commercialization.

Marie Bézenger spent over 20 years within the Chr. Hansen group, one of the world's leading producers of natural ingredients – natural colors, enzymes, probiotics, etc. - for food and health. She has held successively the positions of Head of the Dairy Cultures Department, Innovation Director of Dairy France in the Cultures & Enzymes Division, and also Major Accounts Technical Director. Before joining DEINOVE, she was Director of Operations at Fermentalg. Marie is a food sciences graduate (Polytech Montpellier) and holds a PhD in Biochemistry, Cell & Molecular Biology (University of Montpellier).

"Deinotechnologies have extremely varied applications in many industrial sectors. My mission aims to promote this potential among current and future partners by ensuring the transfer from our laboratory to their plants," says Marie Bézenger.

Emmanuel Petiot, CEO of DEINOVE, adds: "Marie brings strategic know-how to accelerate industrial and commercial dynamics. She will interface with our partners in the deployment of our technologies. We are very pleased to welcome her to our team."

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company’s primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20151005005118/en/